JP7177937B2 - １，２－ジヒドロピリジン化合物の水性医薬製剤 - Google Patents

１，２－ジヒドロピリジン化合物の水性医薬製剤 Download PDF

Info

Publication number
JP7177937B2
JP7177937B2 JP2021530970A JP2021530970A JP7177937B2 JP 7177937 B2 JP7177937 B2 JP 7177937B2 JP 2021530970 A JP2021530970 A JP 2021530970A JP 2021530970 A JP2021530970 A JP 2021530970A JP 7177937 B2 JP7177937 B2 JP 7177937B2
Authority
JP
Japan
Prior art keywords
group
perampanel
pharmaceutical formulation
cyclodextrin
solubilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510947A (ja
JP2022510947A5 (https=
JPWO2020124090A5 (https=
Inventor
ジェフリー エス． ハード，
ガネシュ エス．ピー． ボマレディ，
アンジャリ ジョシ，
ジェームズ マクシェイン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2022510947A publication Critical patent/JP2022510947A/ja
Publication of JP2022510947A5 publication Critical patent/JP2022510947A5/ja
Publication of JPWO2020124090A5 publication Critical patent/JPWO2020124090A5/ja
Application granted granted Critical
Publication of JP7177937B2 publication Critical patent/JP7177937B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021530970A 2018-12-14 2019-12-16 １，２－ジヒドロピリジン化合物の水性医薬製剤 Active JP7177937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779620P 2018-12-14 2018-12-14
US62/779,620 2018-12-14
PCT/US2019/066622 WO2020124090A1 (en) 2018-12-14 2019-12-16 Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds

Publications (4)

Publication Number Publication Date
JP2022510947A JP2022510947A (ja) 2022-01-28
JP2022510947A5 JP2022510947A5 (https=) 2022-06-21
JPWO2020124090A5 JPWO2020124090A5 (https=) 2022-06-21
JP7177937B2 true JP7177937B2 (ja) 2022-11-24

Family

ID=69174604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530970A Active JP7177937B2 (ja) 2018-12-14 2019-12-16 １，２－ジヒドロピリジン化合物の水性医薬製剤

Country Status (11)

Country Link
US (1) US12303499B2 (https=)
EP (1) EP3893844A1 (https=)
JP (1) JP7177937B2 (https=)
KR (1) KR102912861B1 (https=)
CN (1) CN113226286B (https=)
AU (1) AU2019395288B2 (https=)
BR (1) BR112021010953A2 (https=)
CA (1) CA3122705A1 (https=)
MA (1) MA54460A (https=)
MX (1) MX2021006317A (https=)
WO (1) WO2020124090A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014034756A1 (ja) 2012-08-31 2014-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 けいれん重積発作の治療用医薬組成物
CN104644592A (zh) 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种吡仑帕奈药物组合物及其制备方法
CN104706604A (zh) 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
CN106389367A (zh) 2016-11-16 2017-02-15 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
JP2018504420A (ja) 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
HU223945B1 (hu) 1994-09-27 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
US5935551A (en) 1995-11-15 1999-08-10 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite P1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
KR100375155B1 (ko) 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
SK113299A3 (en) 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2007072869A1 (ja) * 2005-12-21 2007-06-28 Eisai R & D Management Co., Ltd. １，２－ジヒドロピリジン化合物の非晶質体
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014034756A1 (ja) 2012-08-31 2014-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 けいれん重積発作の治療用医薬組成物
CN104644592A (zh) 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种吡仑帕奈药物组合物及其制备方法
CN104706604A (zh) 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
JP2018504420A (ja) 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
CN106389367A (zh) 2016-11-16 2017-02-15 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
AU2019395288B2 (en) 2025-04-03
CA3122705A1 (en) 2020-06-18
JP2022510947A (ja) 2022-01-28
BR112021010953A2 (pt) 2021-08-24
US20220023275A1 (en) 2022-01-27
MA54460A (fr) 2021-10-20
CN113226286A (zh) 2021-08-06
KR102912861B1 (ko) 2026-01-15
KR20210107644A (ko) 2021-09-01
AU2019395288A1 (en) 2021-09-23
US12303499B2 (en) 2025-05-20
MX2021006317A (es) 2021-08-11
CN113226286B (zh) 2024-08-20
EP3893844A1 (en) 2021-10-20
WO2020124090A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ES2552386T3 (es) Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
AU2020202577B2 (en) Aripiprazole formulations having increased injection speeds
JP6106228B2 (ja) 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
WO2014161131A1 (en) PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
US20110177161A1 (en) Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
BR122020021551B1 (pt) Composição farmacêutica antimicrobiana e seu uso
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
CN109996787B (zh) 难溶性复合物或其溶剂合物、药物组合物及其应用
JP2016521732A (ja) 安定な抗がん剤のアルギニン塩とそれを含む組成物
JP7177937B2 (ja) １，２－ジヒドロピリジン化合物の水性医薬製剤
AU2004236603B2 (en) Freeze-dried preparation containing methylcobalamin and process for producing the same
RU2824582C2 (ru) Водные фармацевтические составы на основе 1,2-дигидропиридиновых соединений
da Costa et al. Drug-excipient and drug-drug mixtures: a pathway for the production of co-amorphous entities
Chavan et al. Solid state characterization of multicomponent inclusion complex of domperidone with β-cyclodextrin, polyvinyl pyrrolidone and citric acid
CN120676932A (zh) 贝祖拉替尼制剂
Couto Association of capsaicin with local anesthetics to increase analgesia
HK1253589B (zh) 一种苯并二氮杂䓬衍生物的氢溴酸盐及其制备方法和用途
HK1236852A1 (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases
HK1236852B (zh) 用於治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221111

R150 Certificate of patent or registration of utility model

Ref document number: 7177937

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250